dc.contributor.author | Pallesen, Ståle | |
dc.contributor.author | Hamre, HS | |
dc.contributor.author | Lang, Nina | |
dc.contributor.author | Bjorvatn, Bjørn | |
dc.date.accessioned | 2021-05-10T07:30:52Z | |
dc.date.available | 2021-05-10T07:30:52Z | |
dc.date.created | 2021-01-28T10:09:02Z | |
dc.date.issued | 2020 | |
dc.Published | SAGE Open Medical Case Reports. 2020, 8 1-4. | |
dc.identifier.issn | 2050-313X | |
dc.identifier.uri | https://hdl.handle.net/11250/2754484 | |
dc.description.abstract | The α1-adrenergic antagonist prazosin has showed good effect against posttraumatic stress disorder–related nightmares in several randomized controlled trials. The α1-adrenergic antagonist doxazosin, which has a longer half-live than prazosin, has received far less attention in the treatment of such nightmares. Here, we report a case of a patient suffering from severe nightmares following an erroneous medical administration of adrenaline (causing severe physiological hyper-activation) who was treated with doxazosin. Over a period of 280 days, the patient kept a nightmare diary and took 0, 4, or 8 mg doxazosin. The analyses showed that 8 mg doxazosin (55.2% nightmare-free nights) worked better (odds ratio = 28.2; 95% confidence interval = 3.7–213.9) compared to nights without doxazosin (4.3% nightmare-free nights). Except dizziness, which was not regarded as particularly bothersome by the patient, doxazosin was well tolerated. It is concluded that doxazosin may be indicated as a pharmacological treatment for patients suffering from posttraumatic stress disorder–related nightmares. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SAGE Publications | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Doxazosin for the treatment of nightmare disorder: A diary-based case study | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright The Author(s) 2020 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | https://doi.org/10.1177/2050313X20936079 | |
dc.identifier.cristin | 1880986 | |
dc.source.journal | SAGE Open Medical Case Reports | en_US |
dc.source.40 | 8 | |
dc.identifier.citation | SAGE Open Medical Case Reports. 2020, 8. | en_US |
dc.source.volume | 8 | en_US |